JP2020198791A - Sleep-improving composition, and food, drug and feed containing the composition - Google Patents
Sleep-improving composition, and food, drug and feed containing the composition Download PDFInfo
- Publication number
- JP2020198791A JP2020198791A JP2019106129A JP2019106129A JP2020198791A JP 2020198791 A JP2020198791 A JP 2020198791A JP 2019106129 A JP2019106129 A JP 2019106129A JP 2019106129 A JP2019106129 A JP 2019106129A JP 2020198791 A JP2020198791 A JP 2020198791A
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- improving
- composition
- whey protein
- protein hydrolyzate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 235000013305 food Nutrition 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 61
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 61
- 235000021119 whey protein Nutrition 0.000 claims abstract description 59
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 38
- 230000008452 non REM sleep Effects 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 230000001965 increasing effect Effects 0.000 claims abstract description 8
- 102000008192 Lactoglobulins Human genes 0.000 claims abstract description 6
- 108010060630 Lactoglobulins Proteins 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 230000007958 sleep Effects 0.000 claims description 54
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 238000000354 decomposition reaction Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000004622 sleep time Effects 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000004157 Hydrolases Human genes 0.000 description 8
- 108090000604 Hydrolases Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004407 Lactalbumin Human genes 0.000 description 7
- 108090000942 Lactalbumin Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 208000019116 sleep disease Diseases 0.000 description 7
- 235000021241 α-lactalbumin Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 230000000147 hypnotic effect Effects 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- 239000003326 hypnotic agent Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 229940121985 Non-benzodiazepine hypnotic Drugs 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108090001109 Thermolysin Proteins 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003183 myoelectrical effect Effects 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- 108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
- 102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000131 Metalloendopeptidases Proteins 0.000 description 1
- 102000003843 Metalloendopeptidases Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 and feeds Substances 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010043535 protease S Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、睡眠を改善させ、安定性及び安全性に優れた睡眠改善用組成物に関する。また、本発明は、該睡眠改善用組成物を含有する、食品、食品組成物、医薬品、医薬組成物、及び飼料に関する。 The present invention relates to a sleep-improving composition that improves sleep and is excellent in stability and safety. The present invention also relates to foods, food compositions, pharmaceuticals, pharmaceutical compositions, and feeds containing the sleep-improving composition.
近年、ライフスタイルの変化により、生活リズムが乱れ、不眠などの睡眠障害の罹患率が上昇している。厚生労働省の調査によると5人に1人は何らかの睡眠に関する悩みを抱えている(非特許文献1)。睡眠障害は、眠気などによる労働生産性の低下だけでなく、認知症やうつ病などの精神疾患、肥満や糖尿病などの生活習慣病と密接に関連することが明らかとなった。この睡眠不足による経済損失は約3.5兆円になると試算されている(非特許文献2)。 In recent years, changes in lifestyle have disturbed the rhythm of life, and the prevalence of sleep disorders such as insomnia has increased. According to a survey by the Ministry of Health, Labor and Welfare, one in five people has some sort of sleep problem (Non-Patent Document 1). It has been clarified that sleep disorders are closely related not only to the decrease in labor productivity due to drowsiness, but also to mental illnesses such as dementia and depression, and lifestyle-related diseases such as obesity and diabetes. The economic loss due to this lack of sleep is estimated to be about 3.5 trillion yen (Non-Patent Document 2).
不眠などの睡眠障害を持つ人に対しては、医薬品である睡眠薬の使用が考えられる。睡眠薬としては、バルビツール酸系睡眠薬やベンゾジアゼピン系睡眠薬、非ベンゾジアゼピン系睡眠薬が主として用いられている。しかしながら、バルビツール酸系睡眠薬は依存性などの副作用が強く、ベンゾジアゼピン系睡眠薬による睡眠は、ベンゾジアゼピン速波と呼ばれる異常な周波数領域を示す睡眠を誘発するため、生理的で良質な睡眠を導かないことが知られている。また、ベンゾジアゼピン系及び非ベンゾジアゼピン系の睡眠薬は、いずれも、ふらつき、頭痛、めまい等の副作用や入眠までの出来事や中途覚醒時の出来事を覚えていないなどの症状が現れる場合があることが知られている。 For people with sleep disorders such as insomnia, the use of sleeping pills, which are medicines, may be considered. As the hypnotic, barbituric acid hypnotics, benzodiazepine hypnotics, and non-benzodiazepine hypnotics are mainly used. However, barbituric acid hypnotics have strong side effects such as dependence, and sleep with benzodiazepine hypnotics induces sleep showing an abnormal frequency range called benzodiazepine hypnotics, so it should not lead to physiological and good quality sleep. It has been known. In addition, it is known that both benzodiazepine and non-benzodiazepine hypnotics may cause side effects such as light-headedness, headache, dizziness, and symptoms such as not remembering the events leading up to falling asleep or the events during awakening. ing.
このことから、医薬品に代わり日常的に摂取することができ、生理的な睡眠を誘発することができる素材の開発が盛んに実施されており、天然成分や食品成分などから様々なものが提案されている。例えば、アミノ酸であるグリシンによる熟眠障害改善剤(特許文献1)や、テアニンによる睡眠促進組成物(特許文献2)がある。 For this reason, the development of materials that can be taken on a daily basis instead of pharmaceuticals and that can induce physiological sleep is being actively carried out, and various natural ingredients and food ingredients have been proposed. ing. For example, there are a sleep disorder improving agent using glycine, which is an amino acid (Patent Document 1), and a sleep promoting composition using theanine (Patent Document 2).
牛乳や乳製品は古来より食されており、入眠前に加温した牛乳を摂取することで、寝つきが良くなるなど、睡眠が改善されるといわれている。実際にホエイに含まれるαラクトアルブミンによる睡眠改善効果が報告されている(非特許文献3)。また、牛乳カゼイン由来のペプチドによる不安症、睡眠障害及びてんかんを治療できるとする旨の特許が報告されている(特許文献3)。 Milk and dairy products have been eaten since ancient times, and it is said that ingesting warmed milk before falling asleep improves sleep, such as improving sleep. It has been reported that α-lactalbumin actually contained in whey has a sleep improving effect (Non-Patent Document 3). In addition, a patent has been reported that can treat anxiety, sleep disorders, and epilepsy caused by peptides derived from milk casein (Patent Document 3).
しかしながら、前出のαラクトアルブミンの摂取により睡眠改善効果を得るためには、1日あたり40gの摂取が必要であり、日常的に摂取するのは困難である。また、牛乳カゼイン由来のペプチドに関する特許では、不安様行動について動物の行動を目視やビデオ撮影によって評価しているのみであり、該ペプチドが実際に睡眠障害を治療できるかは明らかではなく、実証されたこのペプチドの効果は、抗不安作用に限られる。 However, in order to obtain the sleep improving effect by taking the above-mentioned α-lactalbumin, it is necessary to take 40 g per day, which is difficult to take on a daily basis. In addition, the patent on milk casein-derived peptides only evaluates animal behavior for anxiety-like behavior by visual inspection or videography, and it is not clear or demonstrated whether the peptide can actually treat sleep disorders. The effects of this peptide are limited to anxiety.
本発明は、睡眠を改善させ、安定性及び安全性に優れた睡眠改善用組成物を提供することを課題とする。また、本発明は、該睡眠改善用組成物を含有する食品、食品組成物、医薬品、医薬組成物、及び飼料を提供することを課題とする。 An object of the present invention is to provide a sleep improving composition which improves sleep and is excellent in stability and safety. Another object of the present invention is to provide a food, a food composition, a pharmaceutical product, a pharmaceutical composition, and a feed containing the sleep improving composition.
本発明者らは、上記の課題を解決するため鋭意検討を進めたところ、ホエイタンパク質加水分解物が睡眠を改善させ、その効果は加水分解前のホエイタンパク質よりも有意に強いことを見出した。
すなわち本発明は、以下の様態を含むものである。
(1)ホエイタンパク質加水分解物を有効成分とする睡眠改善用組成物。
(2)前記睡眠改善用組成物が、ノンレム睡眠時間増加用組成物、睡眠時間増加用組成物、及び睡眠導入促進用組成物からなる群より選択される1つ以上であることを特徴とする、(1)に記載の睡眠改善用組成物。
(3)前記ホエイタンパク質加水分解物の分解率が25%以上であることを特徴とする(1)又は(2)のいずれかに記載の睡眠改善用組成物。
(4)前記ホエイタンパク質加水分解物が、以下の特徴を有するものである(1)から(3)のいずれかに記載の睡眠改善用組成物。
(A)分子量分布は10kDa以下、メインピーク200Da〜3kDaである。
(B)APL(平均ペプチド鎖長)は2〜8である。
(C)遊離アミノ酸含量が20%以下である。
(D)抗原性がβ-ラクトグロブリンの抗原性の1/10,000以下である。
(5)前記ホエイタンパク質加水分解物が、ホエイタンパク質をpH6〜10、50〜70℃において耐熱性のタンパク質加水分解酵素を用いて熱変性させながら酵素分解し、加熱して酵素を失活させて得られるものであることを特徴とする(1)から(4)のいずれかに記載の睡眠改善用組成物。
(6)前記ホエイタンパク質加水分解物が、ホエイタンパク質をpH6〜10、20〜55℃においてタンパク質加水分解酵素を用いて酵素分解し、これを50〜70℃に昇温させ、pH6〜10、50〜70℃において耐熱性のタンパク質加水分解酵素を用いて未分解のホエイタンパク質を熱変性させながら酵素分解し、加熱して酵素を失活させて得られるものであることを特徴とする(1)から(4)のいずれかに記載の睡眠改善用組成物。
(7)(1)から(6)のいずれかに記載の睡眠改善用組成物を含むことを特徴とする睡眠改善用食品、睡眠改善用食品組成物、睡眠改善用医薬品、睡眠改善用医薬品組成物、又は睡眠改善用飼料。
As a result of diligent studies to solve the above problems, the present inventors have found that whey protein hydrolyzate improves sleep, and its effect is significantly stronger than that of whey protein before hydrolysis.
That is, the present invention includes the following aspects.
(1) A composition for improving sleep containing a whey protein hydrolyzate as an active ingredient.
(2) The sleep improving composition is one or more selected from the group consisting of a non-REM sleep time increasing composition, a sleep time increasing composition, and a sleep induction promoting composition. , (1). The composition for improving sleep.
(3) The sleep improving composition according to any one of (1) and (2), wherein the decomposition rate of the whey protein hydrolyzate is 25% or more.
(4) The sleep-improving composition according to any one of (1) to (3), wherein the whey protein hydrolyzate has the following characteristics.
(A) The molecular weight distribution is 10 kDa or less, and the main peak is 200 Da to 3 kDa.
(B) APL (mean peptide chain length) is 2-8.
(C) The free amino acid content is 20% or less.
(D) The antigenicity is 1 / 10,000 or less of the antigenicity of β-lactoglobulin.
(5) The whey protein hydrolyzate enzymatically decomposes whey protein at pH 6 to 10 and 50 to 70 ° C. while heat-denaturing it with a heat-resistant protein hydrolase, and heats it to inactivate the enzyme. The composition for improving sleep according to any one of (1) to (4), which is obtained.
(6) The whey protein hydrolyzate enzymatically decomposes whey protein at pH 6 to 10, 20 to 55 ° C. using a protein hydrolyzate enzyme, raises the temperature to 50 to 70 ° C., and pH 6 to 10, 50. It is characterized in that it is obtained by enzymatically decomposing undegraded whey protein using a heat-resistant protein hydrolyzate at ~ 70 ° C while heat-denaturing it, and inactivating the enzyme by heating (1). To the composition for improving sleep according to any one of (4).
(7) A sleep-improving food, a sleep-improving food composition, a sleep-improving drug, a sleep-improving drug composition, which comprises the sleep-improving composition according to any one of (1) to (6). Things or feed for improving sleep.
本発明は、新規な睡眠改善用組成物を提供するものであり、本願でいう睡眠改善とは、ノンレム睡眠時間の増加、1日あたりの睡眠時間の増加、または入眠潜時の短縮の1つ以上を指している。 The present invention provides a novel composition for improving sleep, and the term "sleep improvement" as used herein is one of an increase in non-REM sleep time, an increase in sleep time per day, or a reduction in sleep onset latency. It points to the above.
(睡眠改善用組成物)
本願の睡眠改善用組成物について説明する。
本願の睡眠改善用組成物は、ホエイタンパク質を加水分解したものである。
より具体的には、
ホエイタンパク質加水分解物の分解率が25%以上であり、
分子量分布は10kDa以下、メインピーク200Da〜3kDaであり、
APL(平均ペプチド鎖長)は2〜8であり、
遊離アミノ酸含量が20%以下であり、
抗原性がβ-ラクトグロブリンの抗原性の1/10,000以下、
という特徴を有するものである。
本願の睡眠改善用組成物に使用するホエイタンパク質加水分解物には、全長のαラクトアルブミンは実質的に含まれていない(HPLCによる当該ホエイタンパク質加水分解物の分析結果に基づく。データを示さず。)。より具体的には、当該ホエイタンパク質加水分解物に含まれる全長のαラクトアルブミンの量は、加水分解前のホエイタンパク質に含まれるαラクトアルブミンの量の10%以下、好ましくは、5%以下、2%以下、1%以下、0.5%以下、0.2%以下、又は0.1%以下である。
睡眠改善用組成物のホエイタンパク質加水分解物の分解率は、遊離のアミノ基を修飾して測定するオルトフタルアルデヒド(OPA)法等で測定することができる。ホエイタンパク質加水分解物の分子量分布は、High performance size exclusion chromatography (HPSEC)法等の方法で測定することができる。APL(平均ペプチド鎖長)は、TNBS(2,4,6-トリニトロベンゼンスルホン酸)法等の方法によって測定することができる。遊離アミノ酸含量は、75%エタノール等で遊離アミノ酸を抽出して、アミノ酸分析装置等で測定することができる。抗原性はInhibition ELISA法により評価することができる。
(Sleep improvement composition)
The sleep improving composition of the present application will be described.
The sleep-improving composition of the present application is a hydrolyzed whey protein.
More specifically
The decomposition rate of whey protein hydrolyzate is 25% or more,
The molecular weight distribution is 10 kDa or less, the main peak is 200 Da to 3 kDa, and
APL (mean peptide chain length) is 2-8,
Free amino acid content is 20% or less
Antigenicity is 1 / 10,000 or less of the antigenicity of β-lactoglobulin,
It has the feature.
The whey protein hydrolyzate used in the sleep-improving composition of the present application does not substantially contain full-length α-lactalbumin (based on the analysis results of the whey protein hydrolyzate by HPLC. No data is shown. .). More specifically, the total amount of α-lactalbumin contained in the whey protein hydrolyzate is 10% or less, preferably 5% or less, of the amount of α-lactalbumin contained in the whey protein before hydrolysis. 2% or less, 1% or less, 0.5% or less, 0.2% or less, or 0.1% or less.
The decomposition rate of the whey protein hydrolyzate of the sleep improving composition can be measured by the orthophthalaldehyde (OPA) method or the like, which measures by modifying a free transamination group. The molecular weight distribution of whey protein hydrolyzate can be measured by a method such as High performance size exclusion chromatography (HPSEC) method. The APL (average peptide chain length) can be measured by a method such as the TNBS (2,4,6-trinitrobenzenesulfonic acid) method. The free amino acid content can be measured by extracting free amino acids with 75% ethanol or the like and using an amino acid analyzer or the like. Antigenicity can be evaluated by the inhibition ELISA method.
(睡眠改善用組成物の摂取量)
本発明の睡眠改善用組成物は、上記したように複数のペプチドを含むことから、2つ以上のペプチドの相加・相乗効果により0.01g/日以上の摂取で睡眠改善作用を発現しうる。一方、本発明の睡眠改善用組成物は、抗原性がβ-ラクトグロブリンの1/10,000以下で安全に摂取できるため、摂取量は投与対象者や食品の形態に応じて0.025g/日以上、0.1g/日以上、0.25g/日以上、1g/日以上、又は2.5g/日以上、及び、30g/日以下、20g/日以下、10g/日以下、5g/日以下、2.5g/日以下、又は1g/日以下とすることができる。
本発明の睡眠改善用組成物は、以下に記載のとおり、食品、食品組成物、医薬品、医薬品組成物、及び飼料に添加することができるが、その際の睡眠改善用組成物の添加量は上記した有効量が摂取できるよう適宜調整すればよい。
(Intake of sleep improving composition)
Since the composition for improving sleep of the present invention contains a plurality of peptides as described above, it is possible to exhibit a sleep improving effect at an intake of 0.01 g / day or more due to the additive / synergistic effect of two or more peptides. On the other hand, since the sleep-improving composition of the present invention can be safely ingested with an antigenicity of 1 / 10,000 or less of β-lactoglobulin, the intake amount is 0.025 g / day or more depending on the administration subject and the form of food. 0.1g / day or more, 0.25g / day or more, 1g / day or more, or 2.5g / day or more, and 30g / day or less, 20g / day or less, 10g / day or less, 5g / day or less, 2.5g / day It can be less than or equal to 1 g / day or less.
The sleep-improving composition of the present invention can be added to foods, food compositions, pharmaceuticals, pharmaceutical compositions, and feeds as described below, and the amount of the sleep-improving composition added at that time is It may be adjusted appropriately so that the above-mentioned effective amount can be ingested.
(睡眠改善用組成物の睡眠改善作用の評価方法)
本発明の睡眠改善用組成物の睡眠改善作用は、実施例に記載したラットを対象とした動物試験により確認することができる。
(Evaluation method of sleep improving effect of sleep improving composition)
The sleep-improving effect of the sleep-improving composition of the present invention can be confirmed by the animal test on rats described in Examples.
(睡眠改善用組成物の製造方法)
本発明の睡眠改善用組成物の有効成分であるホエイタンパク質加水分解物は、例えば特開平4-112753号公報で報告されている方法によって得ることができる。この方法では、ホエイタンパク質をpH6〜10、50〜70℃とし、これに耐熱性のタンパク質加水分解酵素を加えて熱変性させながら酵素分解し、これを加熱して酵素を失活させることによって得られる。なお、上記酵素分解を行う前に、ホエイタンパク質をpH6〜10、20〜55℃においてタンパク質加水分解酵素を用いて酵素分解し、これを冷却することなく直ちに上記条件で酵素分解すると収率を一層高めることができる。
(Manufacturing method of sleep improving composition)
The whey protein hydrolyzate, which is the active ingredient of the sleep improving composition of the present invention, can be obtained, for example, by the method reported in JP-A-4-112753. In this method, whey protein is adjusted to pH 6-10, 50-70 ° C, and heat-resistant protein hydrolase is added to it for enzymatic decomposition while heat denaturation, and this is heated to inactivate the enzyme. Be done. Before performing the above enzymatic decomposition, whey protein is enzymatically decomposed at pH 6 to 10 and 20 to 55 ° C. using a protein hydrolase, and the whey protein is immediately enzymatically decomposed under the above conditions without cooling to further increase the yield. Can be enhanced.
また、上記のように調製したホエイタンパク質加水分解物を、分画分子量1kDa〜20kDa、好ましくは、2kDa〜10kDaの限外濾過(UF)膜及び/又は分画分子量100Da〜500Da、好ましくは150Da〜300Daのナノ濾過(NF)膜から選ばれる方法で濃縮することも可能である。このような膜処理により、ホエイタンパク質加水分解物の平均分子量を300〜500Daとすることによって、さらに苦味を軽減し、透明性を向上させることが可能である。 Further, the whey protein hydrolyzate prepared as described above is subjected to an ultrafiltration (UF) membrane having a molecular weight cut off of 1 kDa to 20 kDa, preferably 2 kDa to 10 kDa, and / or a molecular weight cut off from 100 Da to 500 Da, preferably 150 Da to. It is also possible to concentrate by a method selected from 300 Da nanofiltration (NF) membranes. By such a membrane treatment, the average molecular weight of the whey protein hydrolyzate is set to 300 to 500 Da, so that the bitterness can be further reduced and the transparency can be improved.
本発明におけるホエイタンパク質は、ウシやヤギ、ヒツジ、ヒト等の哺乳類の乳から調製したホエイ、その凝集物、粉末、あるいは精製タンパク質をいい、これを酵素反応させる時は水溶液の状態で使用する。 The whey protein in the present invention refers to whey prepared from the milk of mammals such as cows, goats, sheep and humans, its aggregates, powders, or purified proteins, and is used in an aqueous state when it is enzymatically reacted.
特開平4-112753号公報で報告されている方法によってホエイタンパク質加水分解物を調製する場合、前述の溶液をpH6〜10に調整するが、通常ホエイタンパク質はこの範囲のpHになっているので格別pHの調整を行う必要はないが、必要な場合は、塩酸、クエン酸及び乳酸等の酸溶液あるいは苛性ソーダ、水酸化カルシウム及び燐酸ソーダ等のアルカリ溶液を用いてpH6〜10とする。加熱は50〜70℃で行うが、耐熱性のタンパク質加水分解酵素は、この温度で添加するよりも、むしろ加熱前から加え酵素分解を行った方が収率の面から好ましい。 When preparing a whey protein hydrochloride by the method reported in JP-A-4-112753, the pH of the above solution is adjusted to 6 to 10, but the pH of whey protein is usually in this range, so it is exceptional. It is not necessary to adjust the pH, but if necessary, use an acid solution such as hydrochloric acid, citric acid and lactic acid or an alkaline solution such as caustic soda, calcium hydroxide and sodium phosphate to adjust the pH to 6-10. Although heating is carried out at 50 to 70 ° C., it is preferable to add the thermostable protein hydrolase before heating and carry out enzymatic decomposition rather than adding it at this temperature in terms of yield.
また、一般的なプロテアーゼの至適温度は40℃以下であるが、耐熱性のタンパク質加水分解酵素の至適温度は45℃以上であり、耐熱性のタンパク質加水分解酵素としては、従来このような至適温度を有する耐熱性のタンパク質加水分解酵素として知られているものであれば特に制限なく使用できる。このような耐熱性のタンパク質加水分解酵素としては、パパイン、サーモリシン、サーモリシンS、プロテアーゼS(商品名)、プロレザー(商品名)、サモアーゼ(商品名)、アルカラーゼ(商品名)、プロチンA(商品名)等を例示することができる。耐熱性のタンパク質加水分解酵素は、80℃で30分加熱して残存活性が約10%あるいはそれ以上になるものが望ましい。また、単独よりも複数の酵素を併用する方が効果的である。反応は、30分〜10時間程度行うことが好ましい。
最後に、反応液を加熱して酵素を失活させる。酵素の失活は、反応液を100℃以上で10秒間以上加熱することにより行うことができる。
In addition, the optimum temperature of a general protease is 40 ° C. or lower, but the optimum temperature of a heat-resistant protein hydrolase is 45 ° C. or higher. Anything known as a heat-resistant protein hydrolase having an optimum temperature can be used without particular limitation. Examples of such heat-resistant protein hydrolases include papain, thermolysin, thermolysin S, protease S (trade name), proleather (trade name), samoase (trade name), alcalase (trade name), and protein A (trade name). Name) etc. can be exemplified. The thermostable protein hydrolase is preferably heated at 80 ° C. for 30 minutes to have a residual activity of about 10% or more. In addition, it is more effective to use a plurality of enzymes in combination than to use them alone. The reaction is preferably carried out for about 30 minutes to 10 hours.
Finally, the reaction solution is heated to inactivate the enzyme. The inactivation of the enzyme can be performed by heating the reaction solution at 100 ° C. or higher for 10 seconds or longer.
そして反応液を遠心分離して上清を回収し、上清を乾燥して粉末製品とする。なお、遠心分離した時に生ずる沈殿物は上清に比べ低アレルゲン化の程度が小さいので、これを除去した方が好ましいが、勿論反応液をそのまま乾燥して使用しても差し支えない。 Then, the reaction solution is centrifuged to collect the supernatant, and the supernatant is dried to obtain a powder product. Since the degree of allergenization of the precipitate formed during centrifugation is smaller than that of the supernatant, it is preferable to remove it, but of course, the reaction solution may be dried and used as it is.
本発明の睡眠改善用組成物はそのまま使用してもよいが、食品、医薬品、及び飼料に通常含まれる他の原材料とともに使用できることから、常法に従い、粉末剤、顆粒剤、錠剤、カプセル剤、ドリンク剤等に用いることも出来る。また、ヨーグルト、乳飲料、ウエハース等の飲食品、及び飼料に配合することも可能である。 The sleep-improving composition of the present invention may be used as it is, but since it can be used together with other raw materials usually contained in foods, pharmaceuticals, and feeds, powders, granules, tablets, capsules, according to a conventional method, It can also be used as a drink. It can also be added to foods and drinks such as yogurt, milk drinks and wafers, and feed.
以下に実施例、試験例を示し、本発明について詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。 Examples and test examples are shown below, and the present invention will be described in detail, but these are merely examples, and the present invention is not limited thereto.
(実施例1)
ホエイタンパク質10%水溶液1Lに、パパイン50U/g・ホエイタンパク質及びプロレザー(天野エンザイム社製)150U/g・ホエイタンパク質を加え、pH8に調整し、55℃において6時間ホエイタンパク質を変性させながら酵素分解を行った。反応液を100℃で15秒間以上加熱して酵素を失活させ、遠心分離して上清を回収し、これを乾燥してホエイタンパク質加水分解物(実施例品1)を得た。
得られたホエイタンパク質加水分解物の分子量分布は10kDa以下、メインピークは1.3kDa、APLは7.2、すべての構成成分に対する遊離アミノ酸含量は18.9%であった。
Inhibition ELISA法によってβ-ラクトグロブリンに対する抗原性の低下を測定したところ1/10,000以下で、分解率は28%、収率(酵素反応液を遠心分離し、仕込み量の乾燥重量に対する上清の乾燥重量の比率(%))は80.3%であった。
このようにして得られたホエイタンパク質加水分解物は、そのまま本発明の睡眠改善用組成物として使用可能である。
(Example 1)
Papain 50U / g, whey protein and Proleather (manufactured by Amano Enzyme) 150U / g, whey protein are added to 1L of a 10% whey protein aqueous solution, adjusted to pH 8, and the enzyme is denatured at 55 ° C for 6 hours. It was disassembled. The reaction solution was heated at 100 ° C. for 15 seconds or longer to inactivate the enzyme, centrifuged to collect the supernatant, and dried to obtain a whey protein hydrolyzate (Example product 1).
The molecular weight distribution of the obtained whey protein hydrolyzate was 10 kDa or less, the main peak was 1.3 kDa, the APL was 7.2, and the free amino acid content for all the constituents was 18.9%.
The decrease in antigenicity to β-lactoglobulin was measured by the inhibition ELISA method and found to be 1 / 10,000 or less, the decomposition rate was 28%, and the yield (the enzyme reaction solution was centrifuged and the supernatant was dried based on the dry weight of the charged amount. The weight ratio (%)) was 80.3%.
The whey protein hydrolyzate thus obtained can be used as it is as the sleep improving composition of the present invention.
(試験例1)
ホエイタンパク質加水分解物を使用して、睡眠改善効果について評価した。
8週齢のWistar系雄性ラット(日本SLC社)を購入し、12時間ごとの明暗周期の下で、市販固形飼料CRF-1(オリエンタル酵母社製)を与えて、飼料と水を自由に摂取させた。ラットに、脳波及び筋電位を測定するための電極を装着する手術を実施し、回復期として1週間以上の期間をおいて、試験を実施した。
ホエイタンパク質分解物を水に溶解し、ラット体重1kgあたり2.5g経口投与した(FDAのガイドラインをもちいてヒトに換算すると、1日当たり約30gに相当する)、また、比較対象として、ホエイタンパク質濃縮物(タンパク質含量80%)を水に溶解し、ラット体重1kgあたり2.5g経口投与した。投与は17時〜18時(消灯1時間以内)に行い、投与前日の睡眠・覚醒時間と比較した。
脳波及び筋電位は睡眠解析ソフト「スリープサイン」(キッセイコムテック社製、Sleep sign ver2.0)を用いて、覚醒、ノンレム睡眠、レム睡眠の各睡眠ステージに分類した。
投与後12時間の覚醒時間、ノンレム睡眠時間を積算し、投与前日の覚醒時間、ノンレム睡眠時間と比較した。また、Student’s t-testの検定を行い、p<0.05で有意差ありと判定した。
(Test Example 1)
Whey protein hydrolyzate was used to evaluate sleep-improving effects.
Purchased an 8-week-old male Wistar rat (SLC Japan), fed a commercial solid feed CRF-1 (manufactured by Oriental Yeast Co., Ltd.) under a light-dark cycle every 12 hours, and freely ingested feed and water. I let you. Rats were operated on to attach electrodes for measuring brain waves and myoelectric potentials, and the test was conducted with a recovery period of 1 week or longer.
Whey protein degradation products were dissolved in water and orally administered at 2.5 g per 1 kg of rat body weight (corresponding to about 30 g per day when converted to humans using FDA guidelines), and whey protein concentrate for comparison. (Proteo content 80%) was dissolved in water and 2.5 g per 1 kg of rat body weight was orally administered. Administration was performed from 17:00 to 18:00 (within 1 hour after the lights were turned off), and compared with the sleep / wake time on the day before administration.
EEG and myoelectric potential were classified into sleep stages of arousal, non-REM sleep, and REM sleep using the sleep analysis software "Sleep sign" (Sleep sign ver2.0, manufactured by Kissei Comtech).
The awakening time and non-REM sleep time 12 hours after administration were integrated and compared with the awakening time and non-REM sleep time on the day before administration. In addition, Student's t-test test was performed, and it was judged that there was a significant difference when p <0.05.
図1、2に示すように、ホエイタンパク質加水分解物の投与により、投与後12時間のノンレム睡眠時間が、投与前日と比較して有意に増加し、覚醒時間が減少することが示された(投与前日を100%として表す。以下同じ。)。さらに、図3に示すように、ホエイタンパク質加水分解物の投与により、投与直後1時間の睡眠量が有意に増加していることから、睡眠導入作用があることが示唆された。ホエイタンパク質加水分解物には、全長のαラクトアルブミンは含まれていなかったので(HPLCによる当該ホエイタンパク質加水分解物の分析結果に基づく。データを示さず。)、観察された効果はαラクトアルブミンの効果ではない。
一方で、比較対象として用いたホエイタンパク質濃縮物では、投与12時間のノンレム睡眠時間、覚醒時間、及び投与直後1時間のノンレム睡眠時間は、投与前日と比較して差はなかった。
ホエイタンパク質の加水分解に、パパイン及びプロレザーとは異なるプロテアーゼ(システインエンドペプチダーゼ、メタロエンドペプチダーゼ、セリンエンドペプチダーゼ、アスパラギン酸プロテアーゼ)を使用した場合に、図1〜3と同様の結果が得られた(データを示さず)。
As shown in FIGS. 1 and 2, it was shown that the administration of whey protein hydrolyzate significantly increased the non-REM sleep time 12 hours after the administration and decreased the wakefulness time as compared with the day before the administration ( The day before administration is expressed as 100%. The same shall apply hereinafter). Furthermore, as shown in FIG. 3, the administration of whey protein hydrolyzate significantly increased the amount of sleep for 1 hour immediately after administration, suggesting that it has a sleep-inducing effect. Since the whey protein hydrolyzate did not contain full-length alpha-lactalbumin (based on the results of HPLC analysis of the whey protein hydrolyzate, no data shown), the observed effect was alpha-lactalbumin. Is not the effect of.
On the other hand, in the whey protein concentrate used as a comparison target, the non-REM sleep time of 12 hours after administration, the awakening time, and the non-REM sleep time of 1 hour immediately after administration were not different from those on the day before administration.
Similar results to FIGS. 1-3 were obtained when different proteases (cysteine endopeptidase, metalloendopeptidase, serine endopeptidase, aspartic protease) than papain and proleather were used to hydrolyze whey protein. (No data shown).
(実施例品2)睡眠改善用カプセル剤
表1に示す配合で原材料を混合後、常法により造粒し、カプセルに充填して、睡眠改善用カプセル剤を製造した。
(Example product 2) Capsules for sleep improvement After mixing the raw materials with the formulation shown in Table 1, granulated by a conventional method and filled into capsules to produce capsules for sleep improvement.
(実施例品3)睡眠改善用飲料
10gの実施例品1を700gの脱イオン水に添加し、50℃まで加熱後、9,500rpmで30分間撹拌混合した。
前記混合物に表2の原材料を添加した後、100mlのガラス瓶に充填し、95℃、15秒間殺菌後、密栓し、睡眠改善用飲料10本(100ml入り)を調製した。
(Example product 3) Beverage for improving sleep
10 g of Example Product 1 was added to 700 g of deionized water, heated to 50 ° C., and stirred and mixed at 9,500 rpm for 30 minutes.
After adding the raw materials shown in Table 2 to the mixture, the mixture was filled in a 100 ml glass bottle, sterilized at 95 ° C. for 15 seconds, and then sealed to prepare 10 sleep-improving beverages (containing 100 ml).
(実施例品4)イヌ用睡眠改善用飼料
5kgの実施例品1を95kgの脱イオン水に添加し、50℃まで加熱後、3,600rpmで40分間撹拌混合して、実施例品1を5kg/100kg含有する溶液を得た。この溶液20kgに、表3の原材料の全量を混合し、120℃、4分間殺菌して、本発明のイヌ用睡眠改善用飼料100kgを製造した。
(Example product 4) Feed for improving sleep for dogs
5 kg of Example Product 1 was added to 95 kg of deionized water, heated to 50 ° C., and then stirred and mixed at 3,600 rpm for 40 minutes to obtain a solution containing 5 kg / 100 kg of Example Product 1. The whole amount of the raw materials shown in Table 3 was mixed with 20 kg of this solution and sterilized at 120 ° C. for 4 minutes to prepare 100 kg of the feed for improving sleep for dogs of the present invention.
本発明は、新たな睡眠を改善する組成物として、ホエイタンパク質加水分解物を含む組成物と該組成物を含む食品、食品組成物、医薬品、医薬品組成物、及び飼料を提供するものである。本発明の組成物等を摂取することにより睡眠を改善できる。 The present invention provides a composition containing a whey protein hydrolyzate and a food containing the composition, a food composition, a pharmaceutical product, a pharmaceutical composition, and a feed as a new sleep-improving composition. Sleep can be improved by ingesting the composition of the present invention or the like.
Claims (7)
(A)分子量分布は10kDa以下、メインピーク200Da〜3kDaである。
(B)APL(平均ペプチド鎖長)は2〜8である。
(C)遊離アミノ酸含量が20%以下である。
(D)抗原性がβ-ラクトグロブリンの抗原性の1/10,000以下である。 The sleep-improving composition according to any one of claims 1 to 3, wherein the whey protein hydrolyzate has the following characteristics.
(A) The molecular weight distribution is 10 kDa or less, and the main peak is 200 Da to 3 kDa.
(B) APL (mean peptide chain length) is 2-8.
(C) The free amino acid content is 20% or less.
(D) The antigenicity is 1 / 10,000 or less of the antigenicity of β-lactoglobulin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019106129A JP7428480B2 (en) | 2019-06-06 | 2019-06-06 | Compositions for improving sleep and foods, medicines, and feed containing the compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019106129A JP7428480B2 (en) | 2019-06-06 | 2019-06-06 | Compositions for improving sleep and foods, medicines, and feed containing the compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020198791A true JP2020198791A (en) | 2020-12-17 |
JP7428480B2 JP7428480B2 (en) | 2024-02-06 |
Family
ID=73741530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019106129A Active JP7428480B2 (en) | 2019-06-06 | 2019-06-06 | Compositions for improving sleep and foods, medicines, and feed containing the compositions |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7428480B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022202985A1 (en) * | 2021-03-24 | 2022-09-29 | 森永乳業株式会社 | Peptide and composition containing peptide as active ingredient |
WO2023054594A1 (en) * | 2021-09-30 | 2023-04-06 | 雪印メグミルク株式会社 | Method for producing peptide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04112753A (en) * | 1990-08-31 | 1992-04-14 | Snow Brand Milk Prod Co Ltd | Hydrolyzed whey protein having decreased allergen content and production thereof |
WO2005094849A1 (en) * | 2004-03-31 | 2005-10-13 | Calpis Co., Ltd. | Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm |
JP2011523547A (en) * | 2008-04-29 | 2011-08-18 | ディーエスエム アイピー アセッツ ビー.ブイ. | Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan |
JP2012530779A (en) * | 2009-06-22 | 2012-12-06 | エスケー バイオファーマシューティカルズ カンパニー リミテッド | Methods for treating or preventing fatigue |
JP2018008916A (en) * | 2016-07-15 | 2018-01-18 | 株式会社明治 | Agent for promoting rise in amino acid concentrations in blood |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20012319A1 (en) | 2001-11-06 | 2003-05-06 | Mario Baraldi | USE OF MILK SERUM CONTAINING SUBSTANCES IN BENZODIAZEPINO-SIMILE ACTIVITIES |
CN1557475A (en) | 2004-02-04 | 2004-12-29 | 高春平 | Beautifying and fat reducing nutrients composition |
CN1557196A (en) | 2004-02-04 | 2004-12-29 | 高春平 | Pressure regulating, sleep improving natural nutrients |
CN108157963A (en) | 2017-12-25 | 2018-06-15 | 广电计量检测(湖南)有限公司 | Have effects that improve composition, tablet of sleep and preparation method thereof |
-
2019
- 2019-06-06 JP JP2019106129A patent/JP7428480B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04112753A (en) * | 1990-08-31 | 1992-04-14 | Snow Brand Milk Prod Co Ltd | Hydrolyzed whey protein having decreased allergen content and production thereof |
WO2005094849A1 (en) * | 2004-03-31 | 2005-10-13 | Calpis Co., Ltd. | Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm |
JP2011523547A (en) * | 2008-04-29 | 2011-08-18 | ディーエスエム アイピー アセッツ ビー.ブイ. | Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan |
JP2012530779A (en) * | 2009-06-22 | 2012-12-06 | エスケー バイオファーマシューティカルズ カンパニー リミテッド | Methods for treating or preventing fatigue |
JP2018008916A (en) * | 2016-07-15 | 2018-01-18 | 株式会社明治 | Agent for promoting rise in amino acid concentrations in blood |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022202985A1 (en) * | 2021-03-24 | 2022-09-29 | 森永乳業株式会社 | Peptide and composition containing peptide as active ingredient |
WO2023054594A1 (en) * | 2021-09-30 | 2023-04-06 | 雪印メグミルク株式会社 | Method for producing peptide |
Also Published As
Publication number | Publication date |
---|---|
JP7428480B2 (en) | 2024-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5626807B2 (en) | Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan | |
US9993515B2 (en) | Methods of treatment using water-soluble tryptophan-containing peptides obtained by the hydrolysis of hens eggs lysozyme | |
AU2009332369B2 (en) | Muscle-building agent | |
AU2011221852B2 (en) | Agent for preventing muscular atrophy | |
JP2009517464A (en) | Use of protein hydrolysates that enhance the activity of glucagon-like peptide 1 | |
JP7428480B2 (en) | Compositions for improving sleep and foods, medicines, and feed containing the compositions | |
WO2018021471A1 (en) | Food composition for improving brain function | |
JP2004536030A (en) | Method for producing tryptophan-rich peptide | |
JP6041242B2 (en) | Peptides containing tryptophan | |
WO2015166938A1 (en) | Food additive for producing food for preventing cranial nerve disease and/or improving brain function | |
KR20130004284A (en) | Protein synthesis promoter | |
JP2016149989A (en) | Food additive composition for preventing or improving sleep disorder | |
JP7417228B2 (en) | Preventive agents for egg allergy, etc. and food compositions containing the same | |
CN102573880A (en) | Fat accumulation suppressor | |
WO2019151137A1 (en) | Food composition to improve brain function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220428 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230315 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230407 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231004 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240124 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7428480 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |